GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PhotoCure ASA (OTCPK:PHCUF) » Definitions » EV-to-Revenue

PhotoCure ASA (PhotoCure ASA) EV-to-Revenue : 2.65 (As of May. 26, 2024)


View and export this data going back to . Start your Free Trial

What is PhotoCure ASA EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, PhotoCure ASA's enterprise value is $127.11 Mil. PhotoCure ASA's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $48.03 Mil. Therefore, PhotoCure ASA's EV-to-Revenue for today is 2.65.

The historical rank and industry rank for PhotoCure ASA's EV-to-Revenue or its related term are showing as below:

PHCUF' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.75   Med: 4.89   Max: 12.94
Current: 2.65

During the past 13 years, the highest EV-to-Revenue of PhotoCure ASA was 12.94. The lowest was 1.75. And the median was 4.89.

PHCUF's EV-to-Revenue is ranked worse than
55.66% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 2.285 vs PHCUF: 2.65

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-26), PhotoCure ASA's stock price is $5.95. PhotoCure ASA's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $1.78. Therefore, PhotoCure ASA's PS Ratio for today is 3.34.


PhotoCure ASA EV-to-Revenue Historical Data

The historical data trend for PhotoCure ASA's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhotoCure ASA EV-to-Revenue Chart

PhotoCure ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.52 10.02 7.00 6.81 3.18

PhotoCure ASA Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.35 2.18 2.60 3.18 2.41

Competitive Comparison of PhotoCure ASA's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, PhotoCure ASA's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PhotoCure ASA's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PhotoCure ASA's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where PhotoCure ASA's EV-to-Revenue falls into.



PhotoCure ASA EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

PhotoCure ASA's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=127.110/48.031
=2.65

PhotoCure ASA's current Enterprise Value is $127.11 Mil.
PhotoCure ASA's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $48.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PhotoCure ASA  (OTCPK:PHCUF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

PhotoCure ASA's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=5.95/1.78
=3.34

PhotoCure ASA's share price for today is $5.95.
PhotoCure ASA's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.78.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PhotoCure ASA EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of PhotoCure ASA's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


PhotoCure ASA (PhotoCure ASA) Business Description

Traded in Other Exchanges
Address
Hoffsveien 4, Oslo, NOR, 0275
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products specialty pharmaceutical companies. Its technology platform is focused on the field of photodynamic diagnosis and treatment of cancer. It has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, Netherlands, Other European countries, and the United States.